S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
Top-Rated Stocks  
NASDAQ:VRDN

Viridian Therapeutics - VRDN Stock Forecast, Price & News

$37.30
+0.78 (+2.14%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$36.41
▼
$37.65
50-Day Range
$22.61
▼
$37.60
52-Week Range
$9.47
▼
$39.00
Volume
401,924 shs
Average Volume
652,880 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60

Viridian Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
19.6% Upside
$44.60 Price Target
Short Interest
Healthy
8.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of Viridian Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$3.68 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.55) to ($3.33) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

503rd out of 1,053 stocks

Medical Laboratories Industry

16th out of 25 stocks

See Top Rated MarketRank™ Stocks Here

VRDN stock logo

About Viridian Therapeutics (NASDAQ:VRDN) Stock

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VRDN Stock News Headlines

January 31, 2023 | americanbankingnews.com
Jefferies Financial Group Comments on Viridian Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:VRDN)
January 27, 2023 | ca.finance.yahoo.com
Viridian Therapeutics (NASDAQ:VRDN) delivers shareholders solid 105% return over 1 year, surging 4.6% in the last week alone
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 27, 2023 | americanbankingnews.com
Lara Meisner Sells 6,843 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock
January 25, 2023 | seekingalpha.com
Why Viridian Therapeutics Is One Of My 2023 Top Picks
January 11, 2023 | marketwatch.com
Viridian Therapeutics Shares Rise 16% After Positive Trial Data for VRDN-001 Eye Treatment
January 9, 2023 | markets.businessinsider.com
Viridian Announces Positive Data From Phase 1/2 Trial Of Low Dose VRDN-001 In Thyroid Eye Disease
January 9, 2023 | markets.businessinsider.com
Viridian Therapeutics Stock Gains 17%
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 9, 2023 | msn.com
Viridian adds 16% after low dose data for thyroid eye disease candidate
January 8, 2023 | finance.yahoo.com
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
January 3, 2023 | finance.yahoo.com
Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
December 21, 2022 | technews.tmcnet.com
Viridian Therapeutics Announces First Patient Enrolled in the 'THRIVE' Phase 3 Trial in Patients With Thyroid Eye Disease
December 21, 2022 | finance.yahoo.com
Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
December 15, 2022 | seekingalpha.com
Viridian: Better Data Than A Blockbuster Competitor
November 28, 2022 | finance.yahoo.com
Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference
November 17, 2022 | finance.yahoo.com
Wall Street Analysts Predict an 89% Upside in Viridian Therapeutics, Inc. (VRDN): Here's What You Should Know
November 16, 2022 | finance.yahoo.com
Viridian Therapeutics Third Quarter 2022 Earnings: Beats Expectations
November 14, 2022 | finance.yahoo.com
At Higher Dose, Viridian's Thyroid Eye Disease Candidate Shows Significant, Rapid Improvement In Signs & Symptoms
November 14, 2022 | seekingalpha.com
Viridian Therapeutics, Inc. (VRDN) Q3 2022 Earnings Call Transcript
November 14, 2022 | finance.yahoo.com
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
November 14, 2022 | finance.yahoo.com
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
November 14, 2022 | finance.yahoo.com
Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
November 8, 2022 | finance.yahoo.com
Viridian Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 14, 2022
November 8, 2022 | finance.yahoo.com
Viridian Therapeutics to Participate in Guggenheim 4th Annual Neuro/Immunology Conference on November 15th
October 22, 2022 | finance.yahoo.com
Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
October 12, 2022 | finance.yahoo.com
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) Intrinsic Value Is Potentially 97% Above Its Share Price
See More Headlines
Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VRDN Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRDN
CUSIP
N/A
CIK
1590750
Web
www.viridiantherapeutics.com
Phone
(617) 272-4600
Fax
760-537-4101
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.60
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+19.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-79,410,000.00
Net Margins
-6,009.30%
Pretax Margin
-6,009.30%
Return on Equity
-109.29%
Return on Assets
-45.34%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
17.35
Quick Ratio
17.35

Sales & Book Value

Annual Sales
$2.96 million
Price / Sales
358.63
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.48 per share
Price / Book
15.04

Miscellaneous

Outstanding Shares
28,460,000
Free Float
27,189,000
Market Cap
$1.06 billion
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Jonathan ViolinJonathan Violin
    President, Chief Executive Officer & Director
  • Carrie Melvin
    Chief Operating Officer
  • Kristian Franz Humer
    Chief Financial, Accounting & Business Officer
  • Vahe Bedian
    Chief Scientist
  • Barrett Katz
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VRDN Stock - Frequently Asked Questions

Should I buy or sell Viridian Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRDN shares.
View VRDN analyst ratings or view top-rated stocks.

What is Viridian Therapeutics' stock price forecast for 2023?

9 equities research analysts have issued 1-year target prices for Viridian Therapeutics' shares. Their VRDN share price forecasts range from $35.00 to $51.00. On average, they predict the company's share price to reach $44.60 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price.
View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts.

How have VRDN shares performed in 2023?

Viridian Therapeutics' stock was trading at $29.21 at the beginning of the year. Since then, VRDN shares have increased by 27.7% and is now trading at $37.30.
View the best growth stocks for 2023 here.

When is Viridian Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our VRDN earnings forecast.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.01. The business had revenue of $1.20 million for the quarter, compared to analysts' expectations of $0.52 million. Viridian Therapeutics had a negative net margin of 6,009.30% and a negative trailing twelve-month return on equity of 109.29%.

What is Viridian Therapeutics' stock symbol?

Viridian Therapeutics trades on the NASDAQ under the ticker symbol "VRDN."

Who are Viridian Therapeutics' major shareholders?

Viridian Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Moody Aldrich Partners LLC (0.21%), New York State Common Retirement Fund (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner and Life Sciences Public F Frazier.
View institutional ownership trends.

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viridian Therapeutics' stock price today?

One share of VRDN stock can currently be purchased for approximately $37.30.

How much money does Viridian Therapeutics make?

Viridian Therapeutics (NASDAQ:VRDN) has a market capitalization of $1.06 billion and generates $2.96 million in revenue each year. The company earns $-79,410,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis.

How can I contact Viridian Therapeutics?

Viridian Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The official website for the company is www.viridiantherapeutics.com. The company can be reached via phone at (617) 272-4600, via email at daniel@lifesciadvisors.com, or via fax at 760-537-4101.

This page (NASDAQ:VRDN) was last updated on 2/2/2023 by MarketBeat.com Staff